Viking Therapeutics to Attend Investor Conferences - May 30, 2024

Viking Therapeutics, Inc. (NASDAQ: VKTX), a company specializing in the development of innovative therapies for metabolic and endocrine disorders, recently announced its participation in two forthcoming investor conferences. Viking Therapeutics is currently in the clinical-stage of developing several first-in-class and best-in-class therapies.

The first conference, the 2024 Jefferies Global Healthcare Conference, will be held from June 5-6, 2024, at the Marriott Marquis in New York. Viking's management team is scheduled to deliver a corporate presentation and engage in one-on-one meetings. The corporate presentation is set for June 6th, from 10:30 to 10:55 a.m. Eastern Time. For those unable to attend in person, a live webcast of the presentation will be accessible via the Viking Therapeutics website under the Investors & Media section, with a replay available post-conference.

The second event, the Stifel 2nd European Healthcare Summit, will occur from June 25-27, 2024, at the InterContinental Lyon Hotel Dieu in Lyon, France. During this summit, Viking's management will also participate in one-on-one meetings to discuss their ongoing projects and future plans. 

Viking Therapeutics, Inc. is dedicated to developing new therapies aimed at treating metabolic and endocrine disorders. The company currently has three compounds in clinical trials. One of their leading candidates, VK2809, is an orally available, small molecule selective thyroid hormone receptor beta agonist. It is being tested in a Phase 2b study for treating biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a previous Phase 2a trial, VK2809 showed statistically significant reductions in liver fat content and LDL-C levels compared to a placebo in patients with non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C.

Another promising candidate, VK2735, is a dual agonist of the GLP-1 and GIP receptors, intended for the treatment of various metabolic disorders. Data from Phase 1 and Phase 2 trials evaluating subcutaneously dosed VK2735 demonstrated a favorable safety profile and signs of clinical efficacy. The company is also testing an oral formulation of VK2735 in an ongoing Phase 1 trial.

In the realm of rare diseases, Viking is working on VK0214, an orally available, small molecule selective thyroid hormone receptor beta agonist designed for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial involving patients with the adrenomyeloneuropathy (AMN) form of X-ALD.

Viking Therapeutics holds exclusive worldwide rights to a portfolio of five therapeutic programs, which include VK2809 and VK0214, based on small molecules licensed from Ligand Pharmaceuticals Incorporated. The company's research leverages its expertise in metabolism to create treatments aimed at improving patients' quality of life.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!